RxDoctor Payments Data

David Keith, MD

Family Medicine · Fuquay Varina, NCNPI 1639517568

Payments from drug & device makers

$726in general payments, 2019–2025

Across 38 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$169
  • Boston Scientific$106
  • AbbVie$72
  • AstraZeneca$62
  • Lilly USA, LLC$61
  • Amgen$46
  • plus $210 from 9 others

What the payments were for

  • Food & beverage$726100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$726 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$126,707
Medicare patients
314
Services billed
2,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$173,303
EliquisApixaban72$88,422
JardianceEmpagliflozin66$82,058
FarxigaDapagliflozin Propanediol39$55,465
TrulicityDulaglutide18$39,943
MounjaroTirzepatide21$37,604
MyrbetriqMirabegron27$23,296
XareltoRivaroxaban18$16,626
WegovySemaglutide12$15,121
Breo ElliptaFluticasone/Vilanterol21$10,583
Repatha SureclickEvolocumab11$8,574
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$8,436
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,952
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,249
Atorvastatin Calcium479$4,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$169$188,424108 claims
Boehringer IngelheimJardiance$22$82,05866 claims
Lilly USA, LLCTrulicity, Mounjaro$61$77,54739 claims
AstraZenecaFarxiga$62$55,46539 claims
Astellas Pharma US IncMyrbetriq$19$23,29627 claims
AbbVieSynthroid$72$3,46350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Fuquay Varina

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →